Neurocrine Biosciences (NBIX) had the highest return between October 1, 2014 and February 28, 2015 by a large-cap US stock, returning 148.1%.
| ASSET | DATE | % RETURN |
|---|---|---|
Neurocrine Biosciences (NBIX) | 10/1/2014 - 2/28/2015 | 148.09% |
Paycom Software (PAYC) | 10/1/2014 - 2/28/2015 | 96.67% |
Exelixis (EXEL) | 10/1/2014 - 2/28/2015 | 85.44% |
Frontline (FRO) | 10/1/2014 - 2/28/2015 | 81.89% |
Incyte (INCY) | 10/1/2014 - 2/28/2015 | 74.7% |
Genmab A-S (GMAB) | 10/1/2014 - 2/28/2015 | 74.58% |
Halozyme Therapeutics (HALO) | 10/1/2014 - 2/28/2015 | 65.24% |
Lululemon Athletica (LULU) | 10/1/2014 - 2/28/2015 | 63.65% |
Sony (SONY) | 10/1/2014 - 2/28/2015 | 58.3% |
Tower Semiconductor (TSEM) | 10/1/2014 - 2/28/2015 | 57.28% |
MACOM Technology Solutions (MTSI) | 10/1/2014 - 2/28/2015 | 54.96% |
Monster Beverage (MNST) | 10/1/2014 - 2/28/2015 | 54.06% |
Fair Isaac (FICO) | 10/1/2014 - 2/28/2015 | 53.94% |
Stellantis (STLA) | 10/1/2014 - 2/28/2015 | 53.79% |
Axon Enterprise (AXON) | 10/1/2014 - 2/28/2015 | 53.06% |
DexCom (DXCM) | 10/1/2014 - 2/28/2015 | 52.69% |
Skyworks Solutions (SWKS) | 10/1/2014 - 2/28/2015 | 52.67% |
Molina Healthcare (MOH) | 10/1/2014 - 2/28/2015 | 51.64% |
Manhattan Associates (MANH) | 10/1/2014 - 2/28/2015 | 48.94% |
Biomarin Pharmaceutical (BMRN) | 10/1/2014 - 2/28/2015 | 48.85% |
Centene (CNC) | 10/1/2014 - 2/28/2015 | 48.56% |
Coherent (COHR) | 10/1/2014 - 2/28/2015 | 48.47% |
Broadcom (AVGO) | 10/1/2014 - 2/28/2015 | 47.02% |
Smurfit WestRock (SW) | 10/1/2014 - 2/28/2015 | 46.59% |
Palo Alto Networks (PANW) | 10/1/2014 - 2/28/2015 | 45.43% |
Large-cap stocks are treated as having a market cap of $10B+.